

Friday, 14 May, 2021				
	Room 1		Room2	
8:30~8:35	Opening Remarks			
8:35~10:15	Plenary Session 1 : Immunotherapy: Advancement of immunotherapy for childhood cancer			
	Chair	Atsushi Manabe (Hokkaido University Graduate of Medicine)		
	Speakers	Nai-Kong Cheung (Memorial Sloan Kettering Cancer Center, USA) Novel antibody platforms and vaccines for pediatric solid tumors		
		Martin Pule (Cancer Institute, University College London, UK) CD19 and CD22 co-targeting – the UCL experience		
		Shigeki Yagyu (Kyoto Prefectural University of Medicine Graduate School of Medical Science, Japan) piggyBac Transposon-mediated CAR-T cells for solid tumors – a promising approach for clinical application		
		Takahiro Kamiya (Tokyo Medical and Dental University Medical Hospital, Japan) NK cell immunotherapy for childhood cancer: Its' potential advantages and barriers to overcome		
10:15~10:25	Break			
10:25~12:05	Plenary Session 2 : AML target therapy session: Further expectations for targeted therapy in AML		10:30~11:15	Sponsor Seminar 1 (Sponsored by SymBio Pharmaceuticals Limited)
	Chairs	Scott Armstrong (Dana-Farber Cancer Institute)	Chair	Karube Kennosuke (Graduate School of Medicine and Faculty of Medicine, University of the Ryukyus)
		Hitoshi Kiyoi (Nagoya University Graduate School of Medicine)	Speaker	Jo Tomoyasu (Graduate School of Medicine, Kyoto University, Japan) Significance of LUBAC in B-cell lymphoma: Its role in the pathogenesis and treatment
	Speakers	Scott Armstrong (Dana-Farber Cancer Institute, USA) Targeting menin in NPM1 mutant AML		
		Marina Konopleva (The University of Texas MD Anderson Cancer Center, USA) Current and future therapies in acute myeloid leukemia		
		Naomi Kawashima (Nagoya University Graduate School of Medicine, Japan) FLT3 inhibitors: Current progress and underlying drug resistance		
		Takahiro Maeda (Kyushu University Graduate School of Medical Sciences, Japan) Identification of novel targets for AML therapy using functional genomic tools		
12:05~12:15	Break			
12:15~13:00	Luncheon Seminar 1 (Sponsored by Novartis Pharma K.K.)		12:15~13:00	Luncheon Seminar 2 (Sponsored by Otsuka Pharmaceutical Co., Ltd.)
	Chair	Hiroki Yamaguchi (Nippon Medical School)	Chair	Kinuko Mitani (Dokkyo Medical University)
	Speaker	Kensuke Usuki (NTT Medical Center Tokyo, Japan) Treatment of adult aplastic anemia and positioning of eltrombopag	Speaker	Satoshi Takahashi (The Institute of Medical Science, the University of Tokyo, Japan) Cord blood transplant, future perspective
13:00~13:30	Poster Viewing			
13:30~14:30	Asian Session 1 : How to decrease undesired outcomes after allogeneic hematopoietic stem cell transplantation.		13:30~14:50	Asian Session 2 : MPN study in Asia
	Chair	Yoshinobu Kanda (Jichi Medical University Saitama Medical Center)	Chair	Kazuya Shimoda (University of Miyazaki)
	Speakers	Shinichi Kako (Jichi Medical University Saitama Medical Center, Japan) Decreasing GVHD in HLA –mismatched transplantation from haploidentical donor	Speakers	Qian Jiang (Peking University Peoples Hospital, China) Impact of socio-demographic co-variables on disease phase, prognosis, TKI choice and outcomes in persons with newly-diagnosed chronic myeloid leukemia
		Je-Hwan Lee (University of Ulsan, College of Medicine, Korea) Treatment of steroid refractory GVHD		Chih-Cheng Chen (Chang Gung Memorial Hospital, Chang Gung University,Taiwan) Single-cell RNA sequencing discloses distinct transcriptomic profiling in essential thrombocythemia
		Masao Ogata (Oita University Hospital, Japan) Advances in the diagnosis and treatment of HHV-6B encephalitis after allogeneic stem cell transplantation		Kotaro Shide (University of Miyazaki, Japan) Role of driver mutations revealed from MPN mouse models.
				Yoko Edahiro (Juntendo University School of Medicine, Japan) Polycythemia vera in Japanese patients
14:30~16:10	Plenary Session 3 : Recent advances in diagnosis and treatment of lymphoid malignancies			
	Chair	Koji Izutsu (National Cancer Center Hospital)		
	Speakers	Georg Lenz (University Hospital Münster, Germany) Potential targeted therapy for aggressive B-cell lymphoma	15:15~16:00	
		Sattva S. Neelapu (The University of Texas MD Anderson Cancer Center, Houston, Texas, USA) CAR T-cell therapy for B-cell lymphoma	Sponsor Seminar 2 (Sponsored by Sanofi K.K.)	
		Keisuke Kataoka (Keio University School of Medicine, National Cancer Center Research Institute, Japan) Single-cell analysis of the multicellular ecosystem in viral carcinogenesis by HTLV-1	Chair	
		Daisuke Ennishi (Okayama University Hospital, Okayama, Japan) Recent advance of molecular classification of diffuse large B-cell lymphoma ~ toward a new taxonomy ~	Koichi Akashi (Kyushu University Graduate School of Medical Science)	
16:10~16:20	Break			
16:20~18:00	JSH-EHA Joint Session : Development topics of Ph positive leukemia		16:15~17:00	Presidential Special Seminar (Sponsored by Bristol-Myers Squibb K.K.)
	Chair	Shinya Kimura (Saga University)	Chair	Koiti Inokuchi (Nippon Medical School)
	Speakers	Oliver Hantschel (Philipps-University Marburg, Germany) Allosteric targeting of Ph-positive ALL and CML: opportunities to limit drug resistance and to enhance drug selectivity	Speaker	Itaru Matsumura (Kindai University Faculty of Medicine, Japan) Current and future of CML treatment
		Oliver Ottmann (Cardiff University, Cardiff, UK) Philadelphia chromosome positive acute lymphoblastic leukemia – current management		
		Kazuhiro Naka (Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan) Lipid metabolism specific to CML stem cells		
		Hiroshi Ureshino (Saga University, Saga, Japan) Cancer immunology in CML		
			18:15~18:45	Welcome Reception